StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) shareholders

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.63−0.01 (-1.39%)

Close on Nov 17, 2026Market cap $59.90MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
23.8%
23M of 95M shares
Institutional holders
66
4 new, 13 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $32.49K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Aaron G.L. Fletcher
Joint filing with Bios Capital Management, LP (6.80%), Bios Advisors Gp, LLC (6.80%) and 3 more
6,059,5556.90%13D (active) amendmentSep 19, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CGTXValueChange% of portfolio
BIOS Capital Management, LP6,000,0006.31%$6.90M–16.56%
DAVENPORT & Co LLC4,259,5114.48%$4.90M+1,366,7030.02%
Vanguard Capital Management LLC3,438,7753.62%$3.95M+436,9880.00%
BlackRock, Inc.1,261,9931.33%$1.45M+293,6310.00%
Chescapmanager LLC997,0291.05%$1.15M–0.10%
Geode Capital Management, LLC910,0060.96%$1.05M−10,2020.00%
Renaissance Technologies LLC693,2880.73%$797.28K−423,8480.00%
Hilton Capital Management, LLC548,9500.58%$631.29K–0.04%
Vanguard Fiduciary Trust Co508,2200.53%$584.45K+44,5360.00%
CM Management, LLC450,0000.47%$517.50K+50,0000.34%
Dauntless Investment Group, LLC371,7010.39%$427.46K−59,2990.34%
Sigma Planning Corp362,2650.38%$416.61K+24,5000.01%
State Street Corp348,9830.37%$401.33K+34,5000.00%
Tocqueville Asset Management L.P.320,5000.34%$368.58K+125,5000.00%
UBS Group AG218,5360.23%$251.32K+141,6630.00%
American Financial Group Inc205,0000.22%$235.75K–0.08%
Northern Trust Corp178,2020.19%$204.93K+9,5160.00%
Voss Capital, LLC175,0000.18%$201.25K−25,0000.01%
Texas Capital Bank Wealth Management Services Inc143,2960.15%$164.79K+20,0000.01%
Charles Schwab Investment Management Inc84,9400.09%$97.68K–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20266623M23.8%4 / 2310 / 133M1M
Q1 20267521M22.5%13 / 1814 / 145M1M
Q4 20257821M22.6%17 / 1716 / 83M3M
Q3 20256921M22.4%31 / 234 / 812M1M
Q2 20254811M11.8%7 / 107 / 101M1M
Q1 20255112M12.2%11 / 1012 / 41M1M
Q4 20244511M11.7%8 / 129 / 27M0M
Q3 2024404M4.5%10 / 65 / 141M2M
Q2 2024465M5.6%5 / 148 / 61M2M
Q1 2024477M7.5%15 / 910 / 53M3M
Q4 2023377M7.5%7 / 102 / 43M0M
Q3 2023367M7.6%2 / 57 / 10M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

15 funds held CGTX in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CGTXValue% of fundAs of
Vanguard Total Stock Market Index Fund2,444,2952.57%$2.81M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund871,5980.92%$1.00M0.00%Jun 30, 2026
Fidelity Extended Market Index Fund416,1390.44%$491.04K0.00%May 31, 2026
iShares Micro-Cap ETF275,2350.29%$316.52K0.02%Jun 30, 2026
Fidelity Total Market Index Fund143,7710.15%$169.65K0.00%May 31, 2026
Fidelity Series Total Market Index Fund118,7020.12%$140.07K0.00%May 31, 2026
Schwab Total Stock Market Index Fund84,9400.09%$75.56K0.00%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund51,0540.05%$60.24K0.00%May 31, 2026
Vanguard Balanced Index Fund38,7850.04%$44.60K0.00%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund31,7970.03%$36.57K0.00%Jun 30, 2026
Gabelli Global Mini Mites Fund30,0000.03%$34.50K0.13%Jun 30, 2026
1290 VT Micro Cap Portfolio18,3960.02%$21.16K0.01%Jun 30, 2026
iShares Neuroscience and Healthcare ETF4,5430.00%$4.04K0.07%Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund-27,700-0.03%-$31.86K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Lisa RicciardiCEO & President, Director1,754,7021.85%Apr 20, 2026
John Brendan DoyleChief Financial Officer618,9420.65%May 4, 2026
Anthony CaggianoChief Medical Officer874,9060.92%Apr 20, 2026
Aaron G.L. FletcherDirector, 10% owner6,056,2296.37%Jun 22, 2026
Bios Equity Partners, LPDirector, 10% owner––Jun 22, 2026
Ellen B. RichstoneDirector83,5000.09%Jun 22, 2026
Brett P. MoniaDirector73,5000.08%Jun 22, 2026
BIOS Fund I, LPDirector, 10% owner5,505,9055.79%Jun 22, 2026
Bios Equity Partners II, LPDirector, 10% owner6,014,5006.32%Jun 22, 2026
BIOS Capital Management, LPDirector, 10% owner––Jun 22, 2026
BIOS Fund II, LPDirector, 10% owner––Jun 22, 2026
BIOS Fund I QP, LPDirector, 10% owner5,499,9055.78%Jun 22, 2026
Jack A. KhattarDirector73,5000.08%Jun 22, 2026
BIOS Advisors GP, LLCDirector, 10% owner6,048,5006.36%Jun 22, 2026
BIOS Fund II QP, LPDirector, 10% owner––Jun 22, 2026
Peggy WallaceDirector111,4610.12%Jun 22, 2026
BIOS Memory SPV I, LPDirector, 10% owner6,081,2296.39%Jun 22, 2026
BP Directors, LPDirector, 10% owner––Jun 20, 2025
BIOS Equity Partners III, LPDirector, 10% owner––Jun 20, 2025
BIOS Fund III, LPDirector, 10% owner6,048,5006.36%Jun 20, 2025
BIOS Fund III QP, LPDirector, 10% owner5,499,9055.78%Jun 20, 2025
BIOS Fund III NT, LPDirector, 10% owner5,483,8415.77%Jun 20, 2025
BIOS Memory SPV II, LPDirector, 10% owner5,505,9055.79%Jun 20, 2025
Leslie W. KreisDirector, 10% owner6,014,5006.32%Jun 20, 2025
Cavu Advisors, LLCDirector, 10% owner––Jun 20, 2025
Cavu Management, LPDirector, 10% owner5,412,8415.69%Jun 20, 2025
BIOS Fund II NT, LPDirector, 10% owner––Jun 20, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ellen B. Richstone
Director
Jun 17, 2026Award+25,000––83,500
Jack A. Khattar
Director
Jun 17, 2026Award+25,000––73,500
Peggy Wallace
Director
Jun 17, 2026Award+25,000––111,461
BIOS Memory SPV I, LP
Director, 10% owner
Jun 17, 2026Award+25,000––81,229
Brett P. Monia
Director
Jun 17, 2026Award+25,000––73,500
John Brendan Doyle
Chief Financial Officer
May 1, 2026Tax withholding−8,567$1.28$10.97K618,942
John Brendan Doyle
Chief Financial Officer
Apr 16, 2026Buy+10,000$1.13$11.30K627,509
Lisa Ricciardi
CEO & President, Director
Apr 16, 2026Buy+9,175$1.10$10.09K1,715,851
Anthony Caggiano
Chief Medical Officer
Apr 16, 2026Buy+10,000$1.11$11.10K874,906
Lisa Ricciardi
CEO & President, Director
Feb 15, 2026Tax withholding−5,850$1.12$6.55K1,706,676
Anthony Caggiano
Chief Medical Officer
Feb 15, 2026Tax withholding−4,680$1.12$5.24K864,906
John Brendan Doyle
Chief Financial Officer
Feb 15, 2026Tax withholding−1,560$1.12$1.75K617,509
Anthony Caggiano
Chief Medical Officer
Feb 4, 2026Tax withholding−26,919$1.03$27.73K869,586
John Brendan Doyle
Chief Financial Officer
Feb 4, 2026Tax withholding−26,921$1.03$27.73K619,069
Lisa Ricciardi
CEO & President, Director
Feb 4, 2026Tax withholding−51,704$1.03$53.26K1,712,526
Anthony Caggiano
Chief Medical Officer
Feb 3, 2026Award+400,000––907,993
Anthony Caggiano
Chief Medical Officer
Feb 3, 2026Tax withholding−11,488$1.12$12.87K896,505
John Brendan Doyle
Chief Financial Officer
Feb 3, 2026Award+200,000––645,990
Lisa Ricciardi
CEO & President, Director
Feb 3, 2026Award+800,000––1,790,266
Lisa Ricciardi
CEO & President, Director
Feb 3, 2026Tax withholding−26,036$1.12$29.16K1,764,230
John Brendan Doyle
Chief Financial Officer
Dec 18, 2025Award+30,000––455,350
John Brendan Doyle
Chief Financial Officer
Dec 18, 2025Tax withholding−9,360$1.50$14.04K445,990
Anthony Caggiano
Chief Medical Officer
Dec 18, 2025Award+65,000––528,273
Anthony Caggiano
Chief Medical Officer
Dec 18, 2025Tax withholding−20,280$1.50$30.42K507,993
Lisa Ricciardi
CEO & President, Director
Dec 18, 2025Award+75,000––1,013,666
Lisa Ricciardi
CEO & President, Director
Dec 18, 2025Tax withholding−23,400$1.50$35.10K990,266
Aaron G.L. Fletcher
Director, 10% owner
Sep 19, 2025Option exercise+7,729$0.84$6.49K56,229
Lisa Ricciardi
CEO & President, Director
Jul 29, 2025Tax withholding−23,400$0.67$15.68K938,666
Lisa Ricciardi
CEO & President, Director
Jul 29, 2025Award+75,000––962,066
Anthony Caggiano
Chief Medical Officer
Jul 29, 2025Award+65,000––483,554
Anthony Caggiano
Chief Medical Officer
Jul 29, 2025Tax withholding−20,281$0.67$13.59K463,273
John Brendan Doyle
Chief Financial Officer
Jul 29, 2025Tax withholding−9,360$0.67$6.27K425,350
John Brendan Doyle
Chief Financial Officer
Jul 29, 2025Award+30,000––434,710
Brett P. Monia
Director
Jun 18, 2025Award+34,000––48,500
Jack A. Khattar
Director
Jun 18, 2025Award+34,000––48,500
Peggy Wallace
Director
Jun 18, 2025Award+34,000––86,461
Ellen B. Richstone
Director
Jun 18, 2025Award+34,000––58,500
BIOS Advisors GP, LLC
Director, 10% owner
Jun 18, 2025Award+34,000––48,500
BIOS Fund III, LP
Director, 10% owner
Jun 18, 2025Award+34,000––48,500
John Brendan Doyle
Chief Financial Officer
May 1, 2025Tax withholding−9,692$0.45$4.36K404,710
Lisa Ricciardi
CEO & President, Director
Feb 15, 2025Tax withholding−6,619$0.59$3.91K887,066
Anthony Caggiano
Chief Medical Officer
Feb 15, 2025Tax withholding−5,296$0.59$3.12K418,554
John Brendan Doyle
Chief Financial Officer
Feb 15, 2025Tax withholding−1,723$0.59$1.02K414,402
John Brendan Doyle
Chief Financial Officer
Feb 4, 2025Award+295,000––416,125
Anthony Caggiano
Chief Medical Officer
Feb 4, 2025Award+295,000––423,850
Lisa Ricciardi
CEO & President, Director
Feb 4, 2025Award+631,300––893,685
Anthony Caggiano
Chief Medical Officer
Feb 3, 2025Tax withholding−12,779$0.67$8.56K128,850
Lisa Ricciardi
CEO & President, Director
Feb 3, 2025Tax withholding−28,960$0.67$19.40K262,385
Lisa Ricciardi
CEO & President, Director
Jan 31, 2025Buy+38,851$0.77$29.92K38,851
Ellen B. Richstone
Director
Jun 7, 2024Award+8,500––24,500
Brett P. Monia
Director
Jun 7, 2024Award+8,500––14,500
Jack A. Khattar
Director
Jun 7, 2024Award+8,500––14,500
Peggy Wallace
Director
Jun 7, 2024Award+8,500––52,461
Bios Equity Partners II, LP
Director, 10% owner
Jun 7, 2024Award+8,500––14,500
Leslie W. Kreis
Director, 10% owner
Jun 7, 2024Award+8,500––14,500
John Brendan Doyle
Chief Financial Officer
May 1, 2024Tax withholding−8,699$1.95$16.96K121,125
Lisa Ricciardi
CEO & President, Director
Mar 14, 2024Buy+5,700$1.75$9.98K291,345
Lisa Ricciardi
CEO & President, Director
Feb 15, 2024Award+75,000––285,645
Anthony Caggiano
Chief Medical Officer
Feb 15, 2024Award+60,000––141,629
John Brendan Doyle
Chief Financial Officer
Feb 15, 2024Award+20,000––129,824

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
8.11%
7M shares short
Days to cover
15.3
At 0M shares a day
Change since last report
-1.7%
From 7M shares
Short volume, 20 days
45.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cognition Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,196 shares on Sep 18, 2026 over the last 90 days.

See a number that looks wrong?